Status:
COMPLETED
Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborating Sponsors:
Janssen Pharmaceutica
Conditions:
Schizotypal Personality Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this study is to determine the efficacy of risperidone compared to placebo in the treatment of the psychotic-like and deficit symptoms of schizotypal personality disorder (SPD). Treatme...
Detailed Description
All patients receive a comprehensive medical evaluation prior to their participation in any studies, as part of their normal clinical care. The evaluation includes an extensive medical history, physic...
Eligibility Criteria
Inclusion
- Schizotypal Personality Disorder
Exclusion
- Over 65
Key Trial Info
Start Date :
November 1 1995
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2001
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00158028
Start Date
November 1 1995
End Date
December 1 2001
Last Update
August 4 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bronx VA
The Bronx, New York, United States, 10029